Welcome to Immunsystem AB

Clinical phase III study for Anti-Pseudomonas IgY

IMMUNSYSTEM has together with partners in a 7th framework EU project, IMPACTT, been granted over €5 million to conduct a clinical phase III study of Anti-Pseudomonas IgY for the treatment of cystic fibrosis. Currently, multiple CF centers from six European countries have signed on to participate in the study. The EU project is coordinated by Uppsala University.

For additional information, click on the link below.

pdf document Press release (English)


Orphan drug Designation for Anti-Pseudomonas IgY

Swedish biotech company IMMUNSYSTEM I.M.S. AB announces that the European Medicines Agency, EMEA, has granted an orphan drug designation to the drug candidate Anti-Pseudomonas IgY for use in the treatment of cystic fibrosis.

pdf document Orphan drug announcement (English)


Anti-Pseudomonas IgY

Immunotherapy with IgY is by design a low toxicity treatment and is therefore ideally suited for long term prophylaxis, even more so for conditions where it is simply not possible to stay away from the microorganisms that cause the infection.



Cystic Fibrosis

Cystic fibrosis is one of the most common life-shortening, childhood-onset inherited diseases and in caucasian populations, it is the most common life-shortening genetic disease.